Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ono Pharmaceutical Company, Ltd.

https://www.ono-pharma.com

Latest From Ono Pharmaceutical Company, Ltd.

US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption

Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020.  More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.

Pricing Strategies Coronavirus COVID-19

Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022

Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.

Financing Deals

Finance Watch: Five More Small IPOs Squeeze Through The US Window

Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m. 

Financing Business Strategies

SK Bio Eyes Past And Future Milestones On Development Journey

SK Biopharmaceuticals vice-president Haein Shin talks to Scrip about the company’s long journey to developing and launching novel innovative CNS drugs in global markets and what is behind its achievement, which is seen as unprecedented in the South Korean pharma industry.

South Korea Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
    • Ono Pharmaceutical Co., Ltd.
    • Ono Pharma Taiwan Co., Ltd.
UsernamePublicRestriction

Register